Population Pharmacokinetics and Exposure–Safety Relationship of Paclitaxel Liposome in Patients With Non-small Cell Lung Cancer

PURPOSE: Paclitaxel liposome (Lipusu) is the first commercialized liposomal formulation of paclitaxel. There has been little data collected on the pharmacokinetics (PK) of paclitaxel liposome, especially in relation to patient use. This study aimed to build a population pharmacokinetic (PopPK) model...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Haiyan, Yan, Jiaqing, Chen, Wei, Yang, Jun, Liu, Min, Zhang, Yuan, Shen, Xin, Ma, Yinglin, Hu, Xingsheng, Wang, Yan, Du, Kehe, Li, Guohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892953/
https://www.ncbi.nlm.nih.gov/pubmed/33614470
http://dx.doi.org/10.3389/fonc.2020.01731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892953/
https://www.ncbi.nlm.nih.gov/pubmed/33614470
http://dx.doi.org/10.3389/fonc.2020.01731

Ejemplares similares